Long-term analysis of antibodies elicited by SPUTNIK V: A prospective cohort study in Tucumán, Argentina

Chahla, Rossana Elena; Tomas-Grau, Rodrigo Hernán; Cazorla, Silvia I.; Ploper, Diego; Pingitore, Esteban Vera; López, Mónica Aguilar; Aznar, Patricia; Alcorta, María Elena; Vélez, Eva María del Mar; Stagnetto, Agustín; Ávila, César L.; Maldonado-Galdeano, Carolina; Socías, Sergio B.; Heinze, Dar; Navarro, Silvia Adriana; Llapur, Conrado J.; Costa, Dardo; Flores, Isolina; Edelstein, Alexis; Kowdle, Shreyas; Perandones, Claudia; Lee, Benhur; Apfelbaum, Gabriela; Mostoslavsky, Raúl; Mostoslavsky, Gustavo; Perdigón, Gabriela; Chehı́n, Rosana

doi:10.1016/j.lana.2021.100123

Cited by 34 publications

(44 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Notably, the 21.4-fold reduction detected in our study among the BNT162b2-vaccinated group used as control group was in line with other recent publications [ 3 , 4 , 5 , 6 ]. Samples from BNT162b2-vaccinated individuals showed a peak of IgG response at 2 weeks with a significant decrease at the 3 and 6 month timepoints, while, in contrast to previous reports [ 14 , 15 ], Sputnik V sera showed stable IgG dynamics over time. Differences in the studied populations may have an impact on the results, and the samples here analysed for Sputnik V were not longitudinally collected in a follow-up designed trial.…”

Section: Discussioncontrasting

confidence: 98%

Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals

et al. 2022

View full text Add to dashboard Cite

The new Omicron variant of SARS-CoV-2, first identified in November 2021, is rapidly spreading all around the world. Omicron has become the dominant variant of SARS-CoV-2. There are many ongoing studies evaluating the effectiveness of existing vaccines. Studies on the neutralizing activity of vaccinated sera against the Omicron variant are currently being carried out in many laboratories. In this study, we have shown the neutralizing activity of sera against the SARS-CoV-2 Omicron variant compared to the reference Wuhan D614G variant in individuals vaccinated with two doses of Sputnik V up to 6 months after vaccination and in individuals who experienced SARS-CoV-2 infection either before or after vaccination. As a control to our study we also measured neutralizing antibody titers in individuals vaccinated with two doses of BNT162b2. The decrease in NtAb titers to the Omicron variant was 8.1-fold for the group of Sputnik V-vaccinated individuals. When the samples were stratified for the time period after vaccination, a 7.6-fold or 8.8-fold decrease in NtAb titers was noticed after up to 3 and 3-to-6 months after vaccination. We observed a 6.7- and 5-fold decrease in Sputnik V-vaccinated individuals experiencing asymptomatic or symptomatic infection, respectively. These results highlight the observation that the decrease in NtAb to the SARS-CoV-2 Omicron variant compared to the Wuhan variant occurs for different COVID-19 vaccines in use, with some showing no neutralization at all, confirming the necessity of a third booster vaccination.

show abstract

Section: Discussioncontrasting

confidence: 98%

Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals

et al. 2022

View full text Add to dashboard Cite

show abstract

“…These findings were similar to those reported by Yihao et al, where only 28% of the participants immunized with BBIBP-CorV-2 showed, after 180 days, positive neutralizing antibodies [ 25 ]. The NAbs decrease phenomenon, over time, has also been reported in other types of vaccines, such as CoronaVac [ 26 ], BNT162b2 [ 27 , 28 ], mRNA-1273 [ 29 ], Ad26.CoV2.S [ 30 ] and Gam-COVID-Vac [ 31 ]. Nonetheless, even with this decrease, a study found that 97.47% of participants vaccinated with BNT162b2 have shown NAbs until 180 days after, which represents 2.4 times more than observed with BBIBP-CorV-2 [ 32 ], as seen in previously infected BBIBP vaccinated HCWs.…”

Section: Discussionmentioning

confidence: 75%

Humoral Immune Response Induced by the BBIBP-CorV Vaccine (Sinopharm) in Healthcare Workers: A Cohort Study

Torre¹,

Cáceres-DelAguila²,

Muro-Rojo³

et al. 2022

TropicalMed

View full text Add to dashboard Cite

Insufficient data have been reported about the effect of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) on the humoral response through time in healthcare workers (HCW). This retrospective cohort studied the information of 252 HCW from a private laboratory, comparing the antibody-mediated response provoked by BBIBP-CorV between HCW previously infected with SARS-CoV-2 (PI) and not previously infected (NPI), employing the Elecsys® anti-SARS-CoV-2 S and the cPass™ SARS-CoV-2 Neutralization Antibody Detection kit at intervals of 21, 90, and 180 days after vaccination. The presence of neutralizing antibodies in HCW 21 days after full vaccination was 100% in PI and 91.60% in NPI. We observed a progressive decrease in antibody levels over time in both groups. Comparing HCW PI with NPI, PI had a 10.9, 14.3, and 8.6-fold higher antibody titer with the Elecsys® anti-SARS-CoV-2 S at 21 (p < 0.001), 90 (p< 0.001) and 180 days (p < 0.001) respectively, compared to NPI. Using the percent of signal inhibition (PSI) of the antibody neutralization cPass™, HCW PI showed a level of 1.3, 2.0, and 3.1 times more antibodies, at 21 (p < 0.001), 90 (p < 0.001), and 180 days (p < 0.001) respectively, compared to NPI. We determined a progressive decrease in humoral immunity over time, particularly higher in those NPI.

show abstract

“…A study from Argentina observed that Gam-COVID-Vac-elicited high titers of anti-receptor binding domain antibodies beginning to decrease at 60 days, persisting in only 31% at 180 days [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

The impact of COVID-19 vaccination programme in the Republic of San Marino: Focus on effectiveness of Gam-Covid-Vac

Tonnara¹,

Piselli²,

Cimaglia³

et al. 2022

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Long-term analysis of antibodies elicited by SPUTNIK V: A prospective cohort study in Tucumán, Argentina

Cited by 34 publications

References 55 publications

Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals

Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals

Humoral Immune Response Induced by the BBIBP-CorV Vaccine (Sinopharm) in Healthcare Workers: A Cohort Study

The impact of COVID-19 vaccination programme in the Republic of San Marino: Focus on effectiveness of Gam-Covid-Vac

Contact Info

Product

Resources

About